棘阿米巴角膜炎(AK)是一种罕见的,威胁视力的角膜感染。这种疾病的诊断和治疗具有挑战性,变形虫可以迅速封闭,在组织中持续存在并导致复发。药物治疗通常被认为是一线治疗,但晚期病例可能需要更多的侵入性治疗,如“chaud”角膜移植。我们回顾了受AK影响的患者严重并发症的发生率。在筛选的439份报告中,158符合我们的纳入标准。严重并发症的发生率很低,2.21%的患者出现穿孔,1%需要摘除/摘除,不到1%发生眼内炎。16.68%的病例需要角膜移植。根据我们的结果,考虑到这些并发症在其他感染性角膜炎中的发生率,AK患者发生穿孔的总体风险较低,眼内炎,和摘除/摘除内脏。然而,文献中可用的数据仍然很差,我们还需要进一步的随机对照试验来证实我们的发现.
Acanthamoeba keratitis (AK) is a rare, sight-threating corneal infection. The disease is challenging to diagnose and treat, and the amoeba can rapidly encyst, persisting in the tissue and causing recurrences. Medical therapy is conventionally considered the first line treatment, but advanced cases could require more invasive treatments like a \"chaud\" corneal transplant. We review the incidence of severe complications in patients affected by AK. Of 439 reports screened, 158 met our inclusion criteria. Incidence of severe complications was low, with 2.21 % patients developing perforation, 1 % requiring evisceration/enucleation and less than 1 % developing endophthalmitis. Corneal transplantation was required in 16.68 % of the cases. According to our results, and considering the reported incidences of these complications in other infectious keratitis, AK patients have an overall low risk of developing perforation, endophthalmitis, and enucleation/evisceration. Nevertheless, data available in the literature remain poor, and further randomized control trials are needed to confirm our findings.